ClinicalTrials.gg
Active, not recruitingNCT06980805Updated Aug 28, 2026

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

A Phase 2 interventional study of IMVT-1402 and Placebo in Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus, sponsored by Immunovant Sciences GmbH. Active, not recruiting at 86 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.

Planned enrollment
15th of 34
56 · median 46
Started
2025
with 2 others
Phase 2
15 of 39
1 open now
Primary completion
2026-10
later than 1 of 15 live
Registered
33rd of 39
by date

Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 15th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 in phase 2, reaches primary completion later than 1 of the 15 other live ones, and was the 33rd registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.

The study will consist of 3 periods:

Period 1: eligible participants will be randomized 1:1 to IMVT-1402 Dose 1 or placebo SC QW for 12 weeks.

Period 2: participants who completed Period 1 will receive IMVT-1402 Dose 1 SC QW for 14 weeks.

Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks.

Read the detailed description

The total study duration per participant is approximately 61 weeks.

03

Conditions studied

  • Subacute Cutaneous Lupus Erythematosus
  • Chronic Cutaneous Lupus Erythematosus

Keywords

  • Chronic Cutaneous Lupus Erythematosus
  • Subacute Cutaneous Lupus Erythematosus
  • IMVT-1402
  • Imeroprubart
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have documented diagnosis of SCLE or CCLE that has been confirmed by with or without systemic LE manifestations.
  • Have a total CLASI-A score of ≥10 at Screening and Day 1. Participants with a CLASI-A score of ≥8 and \<10 are eligible if the score does not include alopecia and/or mucous membrane lesions.
  • Have active CLE despite an adequate trial of conventional therapies.
  • Are positive for at least one autoantibody at Screening.

Exclusion criteria

Exclusion Criteria:

  • Have known or suspected drug-induced CLE anti-phospholipid disease, or neuropsychiatric SLE.
  • Have rapidly progressive nephritis.
  • Have current inflammatory skin disease other than SCLE/CCLE that, in the opinion of the Investigator, could interfere with the inflammatory skin assessments or confound the disease activity assessments.

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Placebo comparator
    Period 1: Placebo

    Matching placebo for 12 weeks in Period 1

    Drug: Placebo

  • Experimental
    IMVT-1402 Subcutaneous (SC) Once weekly (QW)

    * Period 1: IMVT-1402 Dose 1 SC QW for 12 weeks * Period 2: IMVT-1402 Dose 1 SC QW for 14 weeks * Period 3: IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks

    Drug: IMVT-1402

Interventions

  • Dose 1 or Dose 2 SC QW

  • DrugPlacebo

    Matching Placebo SC QW

06

What researchers measure

Primary outcomes

  1. Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12

    The CLASI-A score represents the overall severity of cutaneous lupus erythematosus (CLE) dermatologic involvement. It is used to assess the activity of mucocutaneous lesions in patients with lupus. The score ranges from 0 (no active lesions) to a maximum of 70. Values between 1 and 9 indicate mild inflammation, 10 to 20 indicate moderate inflammation, and 21 or higher indicate severe inflammation.

    Time frame: Baseline (Day 1) and Week 12

Secondary outcomes

  1. Proportion of participants who have a reduction in CLASI-A score of ≥ 5 points from Period 1 Baseline at Week 12

    Time frame: Baseline (Day 1) and Week 12

  2. Proportion of participants who have a reduction in CLASI-A score of ≥ 50% from Period 1 Baseline at Week 12

    Time frame: Baseline (Day 1) and Week 12

  3. Proportion of participants who have a reduction in CLASI-A score of ≥ 70% from Period 1 Baseline at Week 12

    Time frame: Baseline (Day 1) and Week 12

07

Study locations

86 sites
  • Site Number - 1010
    Anniston, Alabama 36207-4780, United States
  • Site Number - 1020
    Birmingham, Alabama 35203-4050, United States
  • Site Number - 1038
    Phoenix, Arizona 85037, United States
  • Site Number - 1034
    Scottsdale, Arizona 85260, United States
  • Site Number - 1022
    Beverly Hills, California 90211, United States
  • Site Number - 1018
    Chula Vista, California 91910, United States
  • Site Number - 1039
    Corona, California 92882, United States
  • Site Number - 1005
    Fremont, California 94538, United States
  • Site Number - 1023
    Los Angeles, California 90045, United States
  • Site Number - 1000
    Aurora, Colorado 80045-2541, United States
  • Site Number - 1033
    Castle Rock, Colorado 80109-8034, United States
  • Site Number - 1021
    Farmington, Connecticut 06030-2840, United States
  • Site Number - 1014
    Hialeah, Florida 33012, United States
  • Site Number - 1017
    Jacksonville, Florida 32256, United States
  • Site Number - 1028
    Miami, Florida 33122, United States
  • Site Number - 1024
    Miami, Florida 33133, United States
  • Site Number - 1027
    Miami, Florida 33136, United States
  • Site Number - 1011
    Miami Lakes, Florida 33014-5602, United States
  • Site Number - 1025
    Orlando, Florida 32819, United States
  • Site Number - 1009
    Buford, Georgia 30518-8721, United States
  • Site Number - 1030
    Brighton, Massachusetts 02135, United States
  • Site Number - 1019
    Auburn Hills, Michigan 48326-3396, United States
  • Site Number - 1003
    Saint Clair Shores, Michigan 48081-1274, United States
  • Site Number - 1013
    Troy, Michigan 48084 3536, United States
  • Site Number - 1004
    Saint Joseph, Missouri 64506-2459, United States
  • Site Number - 1026
    St Louis, Missouri 63104, United States
  • Site Number - 1007
    Charlotte, North Carolina 28211-1064, United States
  • Site Number - 1008
    Durham, North Carolina 27713-8505, United States
  • Site Number - 1006
    Smithfield, North Carolina 27577-4664, United States
  • Site Number - 1002
    Hershey, Pennsylvania 17033, United States
  • Site Number - 1015
    Philadelphia, Pennsylvania 19103-4708, United States
  • Site Number - 1035
    Houston, Texas 77030, United States
  • Site Number - 1012
    Irving, Texas 75061, United States
  • Site Number -5004
    CABA, 1406, Argentina
  • Site Number - 5000
    CABA, C1023AAB, Argentina
  • Site Number - 5001
    CABA, C1425DND, Argentina
  • Site Number - 5002
    San Miguel de Tucumán, T4000AXL, Argentina
  • Site Number - 5003
    San Miguel de Tucumán, T4000IHE, Argentina
  • Site Number - 5601
    Sofia, 1257, Bulgaria
  • Site Number - 5603
    Sofia, 1431, Bulgaria
  • Site Number - 5600
    Sofia, 1606, Bulgaria
  • Site Number - 5605
    Sofia, 1618, Bulgaria
  • Site Number - 5606
    Sofia, 1680, Bulgaria
  • Site Number - 2000
    Calgary, Alberta T2W 4X9, Canada
  • Site Number - 2002
    Vancouver, British Columbia V5Z 4E8, Canada
  • Site Number - 2003
    Sarnia, Ontario N7T 5W4, Canada
  • Site Number - 5702
    Independencia, 8380000, Chile
  • Site Number - 5704
    Santiago, 7640881, Chile
  • Site Number - 5703
    Santiago, 8320000, Chile
  • Site Number - 5701
    Temuco, 4810345, Chile
  • Site Number - 5700
    Victoria, 4720638, Chile
  • Site Number - 8002
    Tbilisi, 0112, Georgia
  • Site Number - 8000
    Tbilisi, 0160, Georgia
  • Site Number - 6502
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Site Number - 6500
    Erlangen, Bavaria 91054, Germany
  • Site Number - 6501
    Oldenburg, Lower Saxony 26133, Germany
  • Site Number - 6503
    Bochum, North Rhine-Westphalia 44791, Germany
  • Site Number - 3902
    Attiki, Athens 104 31, Greece
  • Site Number - 3901
    Athens, Attica 16121, Greece
  • Site Number - 3903
    Thessaloniki, Central Macedonia 56403, Greece
  • Site Number - 3905
    Thessaloniki, Central Macedonia 56403, Greece
  • Site Number - 3906
    Heraklion, Crete 71110, Greece
  • Site Number - 3900
    Attiki, 12462, Greece
  • Site Number - 3904
    Larissa, 411 10, Greece
  • Site Number - 3004
    Poznan, Greater Poland Voivodeship 60-702, Poland
  • Site Number - 3005
    Gorzów Wielkopolski, Lubusz Voivodeship 66-400, Poland
  • Site Number - 3000
    Warsaw, Masovian Voivodeship 00-716, Poland
  • Site Number - 3001
    Warsaw, Masovian Voivodeship 00-874, Poland
  • Site Number - 3006
    Rzeszów, Pakistan 35-055, Poland
  • Site Number - 3002
    Rzeszów, Podkarpackie Voivodeship 35-309, Poland
  • Site Number - 3003
    Lodz, 90-436, Poland
  • Site Number-1029
    Caguas, 00725-2443, Puerto Rico
  • Site Number - 1037
    Ponce, 00716-0377, Puerto Rico
  • Site Number - 1036
    San Juan, 918, Puerto Rico
  • Site Number - 9000
    Belgrade, 11000, Serbia
  • Site Number - 9001
    Belgrade, 11000, Serbia
  • Site Number - 9003
    Novi Sad, 21000, Serbia
  • Site Number - 7104
    Badalona, Catalonia 8916, Spain
  • Site Number - 7105
    Pamplona, Navarre 31008, Spain
  • Site Number - 7101
    Burjassot, Valencia 46100, Spain
  • Site Number - 7100
    Madrid, 28003, Spain
  • Site Number - 7102
    Madrid, 28041, Spain
  • Site Number - 7103
    Málaga, 29016, Spain
  • Site Number - 7002
    Leeds, West Yorkshire LS7 4SA, United Kingdom
  • Site Number - 7003
    London, SE1 9RT, United Kingdom
  • Site Number - 7000
    Manchester, M15 6SE, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 20, 2025
StartActual
Feb 19, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Apr 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06980805
Lead sponsor
Immunovant Sciences GmbH
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Feb 19, 2025
Primary completion
Oct 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imeroprubart

Start the discussion